Immutep Limited Net Assets
Immutep Limited net assets. Based on the latest financial reports, Immutep Limited (YP1A) has net assets worth €98.90 Million EUR (≈ $115.62 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€147.20 Million ≈ $172.09 Million USD) and total liabilities (€48.30 Million ≈ $56.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Immutep Limited (YP1A) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €98.90 Million |
| % of Total Assets | 67.19% |
| Annual Growth Rate | 32.43% |
| 5-Year Change | 469.15% |
| 10-Year Change | N/A |
| Growth Volatility | 46.17 |
Net Assets of Immutep Limited (2017–2024)
Net assets of Immutep Limited from 2017 to 2024. This chart illustrates how Immutep Limited's net assets have evolved over time, based on quarterly financial data. See Immutep Limited (YP1A) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Immutep Limited (2017–2024)
The table below shows the annual net assets of Immutep Limited from 2017 to 2024. For live market cap and overall valuation, see Immutep Limited (YP1A) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | €189.52 Million ≈ $221.57 Million |
+38.87% |
| 2023-06-30 | €136.47 Million ≈ $159.55 Million |
-0.21% |
| 2022-06-30 | €136.76 Million ≈ $159.88 Million |
+86.65% |
| 2021-06-30 | €73.27 Million ≈ $85.66 Million |
+120.04% |
| 2020-06-30 | €33.30 Million ≈ $38.93 Million |
+36.54% |
| 2019-06-30 | €24.39 Million ≈ $28.51 Million |
-27.25% |
| 2018-06-30 | €33.52 Million ≈ $39.19 Million |
+26.34% |
| 2017-06-30 | €26.53 Million ≈ $31.02 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Immutep Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15080834500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Immutep Limited Net Assets Breakdown (June 2024)
Immutep Limited net assets breakdown by equity component as of June 2024.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €572.17 Million | 301.90% |
| Total Equity | €189.52 Million | 100.00% |
Immutep Limited Competitors by Market Cap
The table below lists competitors of Immutep Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Iskandar Waterfront City Bhd
KLSE:1589
|
$45.10 Million |
|
Beijing JIAYU Door Window Curtain
SHE:300117
|
$45.10 Million |
|
DMS Propertindo Tbk PT
JK:KOTA
|
$45.11 Million |
|
Walkabout Resources Ltd
AU:WKT
|
$45.12 Million |
|
PEH Wertpapier AG
F:PEH
|
$45.09 Million |
|
Green Cross Medical Science Corporation
KQ:142280
|
$45.09 Million |
|
Waskita Beton Precast Tbk PT
JK:WSBP
|
$45.07 Million |
|
Dongbang Agro
KO:007590
|
$45.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immutep Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 136,469,389 to 189,521,742, a change of 53,052,353 (38.9%).
- Net loss of 42,716,625 reduced equity.
- New share issuances of 100,235,538 increased equity.
- Other factors decreased equity by 4,466,560.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-42.72 Million | -22.54% |
| Share Issuances | €100.24 Million | +52.89% |
| Other Changes | €-4.47 Million | -2.36% |
| Total Change | €- | 38.87% |
Book Value vs Market Value Analysis
This analysis compares Immutep Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 21.15x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 21.78x to 21.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-06-30 | €0.13 | €2.76 | x |
| 2018-06-30 | €0.11 | €2.76 | x |
| 2019-06-30 | €0.07 | €2.76 | x |
| 2020-06-30 | €0.07 | €2.76 | x |
| 2021-06-30 | €0.10 | €2.76 | x |
| 2022-06-30 | €0.16 | €2.76 | x |
| 2023-06-30 | €0.11 | €2.76 | x |
| 2024-06-30 | €0.13 | €2.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immutep Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-22.54%) is above the historical average (-39.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -35.30% | 0.00% | 0.00x | 1.32x | €-12.02 Million |
| 2018 | -38.02% | -484.55% | 0.06x | 1.40x | €-16.10 Million |
| 2019 | -75.22% | -13123.28% | 0.00x | 1.66x | €-20.78 Million |
| 2020 | -40.45% | -179.90% | 0.16x | 1.40x | €-16.80 Million |
| 2021 | -40.81% | -24929.03% | 0.00x | 1.12x | €-37.23 Million |
| 2022 | -34.24% | -18906.51% | 0.00x | 1.09x | €-60.50 Million |
| 2023 | -29.23% | -23417.61% | 0.00x | 1.08x | €-53.54 Million |
| 2024 | -22.54% | 0.00% | 0.00x | 1.06x | €-61.67 Million |
Industry Comparison
This section compares Immutep Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immutep Limited (YP1A) | €98.90 Million | -35.30% | 0.49x | $45.10 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more